Loading…
Employees: 258
Size Geron (GERN) is a United States Health Care company (Biotechnology) with a market value of $636M, the 2552nd largest of 3,117 United States companies the cockpit tracks. Shares closed at $0.99 on 6 Nov 2026.
Performance Over six months the shares fell 28.8%, against -13.7% for the median peer and -1.1% for the United States market (cap-weighted) — 5th lowest of 19 in its peer set.
Growth Revenue grew 18.6% over the last twelve months (peer median +17.8%); the operating margin is -8.2% (peer median -139.9%).
Valuation It trades at 16.7× forward earnings against a peer median of 52.4× (cheapest of 5).
Short interest Short interest is 11.6% of the free float (15 Oct 2026).
Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $218M | $184M | $77.0M | $237,000 | $596,000 |
| Revenue growth | — | +139% | +32,387% | -60% | — |
| Gross profit | $206M | $179M | $75.7M | -$796,000 | -$272,000 |
| EBITDA | n/a | -$50.3M | -$173M | -$193M | -$138M |
| Net income | -$50.1M | -$83.5M | -$175M | -$184M | -$142M |
| Free cash flow | n/a | -$111M | -$219M | -$169M | -$128M |
| Capital expenditure | n/a | $49,000 | $680,000 | $830,000 | $431,000 |
| Total debt | n/a | $252M | $247M | $85.9M | $55.8M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | GERN | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -18.9% | -9.7% | 4th lowest of 21 |
| 6-month return | -28.8% | -13.7% | 5th lowest of 19 |
| Distance from 52-week high | -50.8% | -43.2% | 7th lowest of 21 |
| Revenue growth (TTM) | +18.6% | +17.8% | 7th highest of 13 |
| Operating margin | -8.2% | -139.9% | 5th highest of 14 |
| Forward P/E | 16.7× | 52.4× | cheapest of 5 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Geron GERN | United States | $636M | -29% | +19% | -8% | 16.7× | n/a | n/a |
| Design Therapeutics DSGN | United States | $639M | -28% | n/a | n/a | n/a | n/a | n/a |
| Apnimed APMD | United States | $629M | n/a | +380% | -140% | n/a | n/a | n/a |
| Kura Oncology KURA | United States | $647M | -23% | -7% | -412% | n/a | n/a | n/a |
| Getein Biotech 603387.SS | China | $647M | -12% | +8% | 21% | n/a | -8.3% | -1.3% |
| Ascletis Pharma 1672.HK | Hong Kong | $610M | -73% | -59% | -71,976% | n/a | n/a | n/a |
| Wave Life Sciences WVE | United States | $664M | -53% | -35% | -321% | n/a | n/a | n/a |
| Boji Medical Technology 300404.SZ | China | $664M | +7% | +32% | 4% | 82.0× | 35.4% | +27.2% |
| Candel Therapeutics CADL | United States | $670M | +5% | n/a | n/a | n/a | n/a | n/a |
| 4D Molecular Therapeutics FDMT | United States | $677M | +21% | +278,712% | -214% | n/a | n/a | n/a |
| Aura Biosciences AURA | United States | $680M | -22% | n/a | n/a | n/a | n/a | n/a |
| Genfit GNFT.PA | France | $593M | +19% | +28% | -130% | 79.3× | 40.0% | +143.5% |
| Shenzhen Weiguang Biological Products 002880.SZ | China | $682M | -22% | 0% | 18% | 20.7× | n/a | n/a |
| Climb Bio CLYM | United States | $591M | -10% | n/a | n/a | n/a | n/a | n/a |
| Anhui Huaheng Biotechnology 688639.SS | China | $688M | -40% | +7% | 3% | 25.4× | n/a | n/a |
| Attovia Therapeutics ATTO | United States | $697M | +744% | n/a | -4,975% | n/a | n/a | n/a |
| Alebund Pharmaceuticals (Jiangsu) 9637.HK | Hong Kong | $576M | n/a | +674% | -495% | n/a | n/a | n/a |
| Solid Biosciences SLDB | United States | $707M | -9% | n/a | n/a | n/a | n/a | n/a |
| Sana Biotechnology SANA | United States | $709M | -32% | n/a | n/a | n/a | n/a | n/a |
| Faeth Therapeutics FTH | United States | $570M | -6% | n/a | n/a | n/a | n/a | n/a |
| Shouyao Holdings Beijing 688197.SS | China | $726M | -16% | +4,564% | -92% | n/a | n/a | n/a |